2026-06-30T02:01:15Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/88772025-04-22T13:13:20Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16927col_20.500.12105_16969col_20.500.12105_16978col_20.500.12105_16984

00925njm 22002777a 4500 dc Lopez-Tarruella, Sara author Escudero, M J author Pollan-Santamaria, Marina author Martín, Miguel author Jara, Carlos author Bermejo, Begoña author Guerrero-Zotano, Ángel author García-Saenz, José author Santaballa, Ana author Alba, Emilio author Andrés, Raquel author Martínez, Purificación author Calvo, Lourdes author Fernández, Antonio author Batista, Norberto author Llombart-Cussac, Antonio author Antón, Antonio author Lahuerta, Ainhara author de la Haba, Juan author López-Vega, José Manuel author Carrasco, E author 2019-12-27 The debate about surgical resection of primary tumor (PT) in de novo metastatic breast cancer (MBC) patients persists. We explored this approach's outcomes in patients included in a retrospective registry, named El Álamo, of breast cancer patients diagnosed in Spain (1990-2001). In this analysis we only included de novo MBC patients, 1415 of whom met the study's criteria. Descriptive, Kaplan-Meier and Cox regression analyses were carried out. Median age was 63.1 years, 49.2% of patients had single-organ metastasis (skin/soft tissue [16.3%], bone [33.8%], or viscera [48.3%]). PT surgery (S) was performed in 44.5% of the cases. S-group patients were younger, had smaller tumors, higher prevalence of bone and oligometastatic disease, and lower prevalence of visceral involvement. With a median follow-up of 23.3 months, overall survival (OS) was 39.6 versus 22.4 months (HR = 0.59, p < 0.0001) in the S- and non-S groups, respectively. The S-group OS benefit remained statistically and clinically significant regardless of metastatic location, histological type, histological grade, hormone receptor status and tumor size. PT surgery (versus no surgery) was associated with an OS benefit suggesting that loco-regional PT control may be considered in selected MBC patients. Data from randomized controlled trials are of utmost importance to confirm these results. Sci Rep. 2019 Dec 27;9(1):20081. 10.1038/s41598-019-55765-9 2045-2322 2045-2322 Scientific reports http://hdl.handle.net/10668/14894 31882586 http://hdl.handle.net/20.500.12105/8877 Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)